| |
No change of DMARD
|
Change of DMARD
|
Reason for change
|
|---|
|
Adverse drug reaction
|
Lack of efficacy
|
|---|
|
N
|
356
|
410
|
139
|
230
|
|
Female
|
65%
|
72% *
|
71%
|
72%
|
|
Age (yrs)
|
58 (47–68)
|
56 (46–66)
|
60 (50–70)
|
54 (44–63) **
|
|
BMI (kg/m2)
|
26.4 (23.9 - 30.1)
|
26.9 (23.7 - 30.8)
|
26.6 (23.8 - 30.5)
|
27.2 (23.9 - 31.2)
|
|
Ever smoked
|
57%
|
65% *
|
66%
|
65%
|
|
Current smoker
|
35%
|
39%
|
39%
|
37%
|
|
Symptom duration (mo)
|
6 (4–12)
|
6 (4–12)
|
5 (3–10)
|
6 (3–13)
|
|
Erosions
|
47%
|
26%
|
23%
|
28%
|
|
HAQ (0–3)
|
1.0 (0.4 - 0.6)
|
1.4 (0.8 - 1.9) **
|
1.3 (0.6 - 1.8) *
|
1.4 (0.8 - 1.9) **
|
|
>4 of 1987 ACR criteria
|
51%
|
59% *
|
53%
|
65% **
|
|
Seropositive
|
62%
|
61%
|
54%
|
64%
|
|
Extra-articular disease
|
11%
|
20% **
|
15%
|
24% **
|
|
Co-morbidity
|
44%
|
50%
|
56% *
|
49%
|
|
DAS28
|
4.6 (3.6 - 5.7)
|
5.1 (4.0 - 6.1) **
|
4.8 (3.5 - 5.7)
|
5.4 (4.1 - 6.2) **
|
|
DAS28-P (0–1)
|
0.41 (0.32 - 0.47)
|
0.43 (0.35 - 0.50) **
|
0.42 (0.32 - 0.50)
|
0.43 (0.37 - 0.50) **
|
|
SF36-Bodily pain (0–100)
|
41 (31–62)
|
32 (22–51) **
|
41 (22–62) *
|
31 (21–42) **
|
|
SF36-Mental Health (0–100)
|
68 (52–80)
|
60 (48–72) **
|
60 (48–72) **
|
56 (48–70) **
|
|
Steroid at baseline
|
17%
|
16%
|
14%
|
16%
|
|
Sulphasalazine monotherapy
|
27%
|
43%
|
59%
|
33%
|
|
Methotrexate monotherapy
|
53%
|
36%
|
23%
|
48%
|
|
Other monotherapy
|
4%
|
11%
|
9%
|
12%
|
|
Dual therapy
|
6%
|
5%
|
7%
|
4%
|
|
Triple therapy
|
10%
|
4%
|
2%
|
4%
|
- Comparison of patient groups based upon DMARD changes. Medians (IQR) or percentage prevalences are presented. ** p < 0.01, * p < 0.05 for comparison vs No Change. Statistically significant results are presented in bold (with the exception of DMARD treatments, which were also significantly heterogeneous, but tested as a group).
